Articles tagged with Breast Cancer
Researchers will identify biomarkers for DNA repair defects in tumors, enabling faster decision-making on treatment choices. A clinical trial will test carboplatin therapy's effectiveness in advanced prostate cancer.
A recent study published in the British Journal of Cancer found a positive association between type 2 diabetes and an increased risk of colorectal cancer (CRC) in men, with a moderately higher risk observed. In contrast, the association was weaker and not statistically significant for women. The study followed up over 87,000 women and ...
A synthetic compound based on a brain hormone has shown surprising benefits in treating lung and other cancers in mice, but its effect on human cells was the opposite. The compound, MR409, is one of several GHRH analogs that spur healthy tissue growth and may alleviate concerns about stimulating cancer cell growth.
A study of genetic variants found that morning preference reduces the risk of breast cancer by 40-48% compared to evening types. Increased sleep duration and insomnia were associated with a 20% increased risk of breast cancer.
A study published in Psycho-Oncology found that women who have survived breast cancer are more likely to experience phobic anxiety, leading to sexual dysfunction and unpleasant sex experiences. The research highlights the significant role of psychosocial factors on sexuality in these patients.
A prognostic model using machine learning accurately stratifies African-American breast cancer patients into high- and low-risk populations based on protein expression levels. The model identifies a combination of four proteins associated with increased risk of death, suggesting specific therapeutic regimens for this underserved demogr...
A new study reveals that states expanding Medicaid from 2011 to 2017 experienced a significant 27% increase in prescriptions for hormonal therapy medications compared to non-expansion states. This rise was attributed to increased access for previously uninsured women who required long-term treatment with these life-saving drugs.
Women carrying rare breast cancer variants are more likely to develop interval breast cancers, which are often aggressive and lethal. The study found that these women have a higher risk of death from breast cancer compared to those with common mutations.
Researchers at the University of Cincinnati have developed a molecular diagnostic test that can assess breast cancer risk based on Osteopontin variants. The test helps patients and doctors make informed decisions about treatment options, weighing aggressive intervention against waiting for potential progression.
A new study finds that women receiving hormone-blocking injections during chemotherapy have a higher chance of becoming pregnant without negative side effects. The injections protect the ovaries from chemotherapy's effects, reducing the risk of early menopause and improving survival rates.
Long-term data show that whole breast radiation therapy significantly reduces the risk of local recurrence in low-risk ductal carcinoma in situ (DCIS) patients, even without additional treatment. Radiation also reduces overall cancer return by more than 70 percent.
Researchers investigated alternative radiation therapy regimens for early-stage breast cancer patients. The trial found that fewer, larger individual doses of radiation led to similar adverse effects as conventional radiation therapy after 10 years.
Researchers found that common genetic variations can significantly increase breast cancer risk for female pediatric cancer survivors, with a two-fold higher risk compared to average survivors. The collective effect of these variations is comparable to having a high-risk mutation in breast cancer predisposition genes.
A study of female childhood cancer survivors found that genetic profiling can identify high-risk individuals for subsequent breast cancer. Polygenic determinants and rare mutations significantly contribute to breast cancer risk, with a notable age-specific association in younger women.
A survey of 724 women found that nearly 60% knew about the link between breastfeeding and breast cancer risk reduction, but only 16% learned it from a medical professional. The study highlights the importance of healthcare providers educating mothers about the benefits of breastfeeding in reducing breast cancer risk.
A phase III clinical trial found that palbociclib improves overall survival in women with hormone receptor-positive metastatic breast cancer. The drug, used in combination with standard treatment, led to a clinically meaningful improvement in median overall survival, even in patients who showed sensitivity to prior hormone therapy.
Researchers found that half of the Spanish-speaking women did not receive letters in their native language, leading to confusion and misinterpretation of key messages. The study highlights the importance of culturally sensitive communication and timely follow-up for women with dense breasts.
Researchers developed a nanofluidic seed that can deliver sustained-release doses of immunotherapy directly to tumors, reducing the need for multiple IV treatments and eliminating side effects. The device has shown promising results in mice models, with equal effectiveness compared to systemic immunotherapy while minimizing toxicities.
The HOBOE-2 trial found that zoledronic acid plus letrozole improved disease-free survival in premenopausal women with HR+ early breast cancer, with a 5-year DFS probability of 0.93 compared to 0.85 for tamoxifen. The combination treatment reduced breast cancer recurrence and mortality by nearly half.
A study published in Nature Genetics found that long non-coding RNA MALAT1 suppresses breast cancer metastasis, contradicting its previously described role as a metastasis promoter. The researchers used mouse models to show that MALAT1 binds and inactivates TEAD, a transcription factor involved in promoting metastasis.
A phase III trial demonstrated that chidamide, an HDAC inhibitor, improves progression-free survival compared to placebo plus exemestane in patients with hormone receptor-positive advanced breast cancer. Serious adverse events were reported, but the treatment regimen was generally well-tolerated.
A new study shows that targeting the specific genomic mutation PIK3CA in hormone receptor-positive HER2-negative advanced breast cancer patients significantly improves progression-free survival. The study found that nearly twice as long PFS was observed in patients with PIK3CA mutations treated with alpelisib compared to the placebo gr...
The PALOMA-3 study found that the CDK4/6 inhibitor palbociclib significantly improves progression-free survival in patients with HR+/HER2- advanced breast cancer. In a new analysis, palbociclib plus fulvestrant was shown to improve overall survival by 6.9 months compared to placebo plus fulvestrant.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
A Phase III clinical trial shows that combining immunotherapy with chemotherapy improves progression-free and overall survival for patients with triple-negative breast cancer. The study's results establish a new standard of care in PD-L1+ patients and provide hope for those diagnosed with this aggressive form of breast cancer.
A combination of immunotherapy and chemotherapy significantly extends survival by up to ten months in patients with triple-negative breast cancer. The treatment reduces the risk of death or cancer progression by up to 40 per cent, offering new hope for young women affected by this aggressive form of breast cancer.
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer. The combination treatment lived seven months longer than hormone treatment alone, with benefits strongest in women who had previously responded to hormone therapy.
A recent survey found that social vulnerability and medical skepticism are major barriers to cancer screening participation, particularly for colorectal and lung cancer screenings. Researchers call for a combined approach incorporating new technologies and personalized messaging to address inequalities in screening uptake.
French researchers conclude that including exercise in cancer care can significantly improve symptom management, quality of life, and fitness. Studies show that regular exercise reduces pain, fatigue, and body fat while improving overall fitness, with benefits seen even among patients at highest risk of poor quality of life.
A nine-week course of adjuvant trastuzumab was associated with similar disease-free survival and lower risk of cardiac toxicity compared to a one-year course in patients with HER2-positive early breast cancer. A six-month course of trastuzumab was also shown to be cost-effective, with an average cost saving of nearly £10,000 per patient.
A study of breast cancer survivors found that natural pregnancies are possible after chemotherapy, but many no longer wish to have children. The study also showed that fertility preservation measures are not widely needed among young breast cancer patients.
A French prospective study found that nearly one in six premenopausal women with early-stage breast cancer do not adequately adhere to tamoxifen therapy after one year, potentially leading to increased risk of recurrence. The study aimed to identify clinical and social characteristics associated with poor adherence to endocrine therapy.
The Case Comprehensive Cancer Center has received a $3 million NIH grant to investigate racial disparities in colorectal and breast cancer. The research program aims to identify genetic biomarkers for cancer specific to high-risk populations and promote medical and social policies that benefit communities.
A new statistical method estimates the short- and long-term risk of recurrence for hormone receptor-positive and HR-negative breast cancers in US women. The study found that while HR-positive breast cancer has a lower risk of progression to metastatic disease soon after diagnosis, the risk persists for several years.
A University of Cincinnati researcher is working on a new light therapy that uses ultraviolet light to activate light-sensitive drugs, selectively targeting cancer cells while sparing healthy stem cells. This approach has the potential to be more effective and safer than current treatments.
A deep-learning model has been successfully used on real patients to assess dense breast tissue in mammograms with high accuracy. The model outperforms traditional prediction models, achieving a kappa score of 0.85 in clinical applications, and could lead to more consistent screening procedures nationwide.
A study comparing DNA and RNA data from Nigerian breast cancer patients to those in a US database found aggressive molecular features prevalent in tumors from Nigerian women, which could explain disparities in breast cancer mortality. The study highlights the potential for targeted therapies to reduce mortality gap.
A diet high in omega-3 fatty acids from fish oil may delay the development and spread of breast cancer cells in mice. The study found that these cells took significantly longer to form tumors and grew smaller over time.
A new AI algorithm measures breast density at a high level of accuracy, comparable to experienced mammographers. The system has been successfully implemented in routine clinical practice and has the potential to standardize and automate breast density assessment.
A major clinical study in Sweden has shown that 3D mammography detects over 30% more cancers compared to traditional mammography. The method uses low-dose x-ray images from different angles, resulting in higher image quality and increased cancer detection rates.
A new blood test offers a safer approach than surgical biopsies and allows doctors to monitor treatment effectiveness even before changes are identified on scans. The study found that circulating tumor DNA in the blood or cerebrospinal fluid can reveal a driver mutation in 42 of 48 patients, indicating the tumor's genetic signature.
Researchers have developed a new method for imaging breast cancer using Cornell dots, which are smaller than 8 nanometers and can be cleared by the kidneys. The dots are equipped with antibody fragments that target HER2-positive breast cancer cells, achieving high in vivo tumor uptake rates of up to 17.2 percent.
A new report reveals a protein, deltaNp63, that directs myeloid-derived immunosuppressor cells (MDSCs) to the primary tumor and metastatic sites, promoting tumor growth and metastasis. Blocking deltaNp63 or MDSCs reduced tumor growth and metastasis in a mouse model of triple-negative breast cancer.
A recent study analyzed over 6,000 tweets about breast cancer and found that 90% of medical information was appropriate, with prevention being the most common subtheme. The study suggests that social media can be a valuable tool for providing information on cancer prevention and health education.
A study of nearly 600 women with breast cancer found that autologous fat transfer did not increase rates of cancer relapse after five years. While the study did not show significant differences, it highlights the potential benefits of this technique for correcting deformities after breast cancer surgery.
A study of 178 countries found a strong negative correlation between family size and cancer incidence, with larger families having a protective effect against various types of cancer. The protective effects are stronger for males than females, with non-reproduction-related cancers also being involved.
The Society of Breast Imaging has partnered with Oxford University Press to launch the Journal of Breast Imaging, providing a platform for high-quality, evidence-based content on breast imaging. The journal aims to advance the field of breast imaging, improving patient care and outcomes.
Three leading researchers, Ian Smith, Ann Partridge, and Zena Werb, receive top honors for their groundbreaking work on breast cancer treatment and research. Their contributions have propelled advances in breast cancer science and medicine, saving countless lives from the disease.
A study of over 6,000 patients with advanced cancer treated in community settings shows that nearly a quarter received targeted treatment based on DNA mutations. This achievement marks a significant shift towards precision medicine, allowing more patients to benefit from innovative therapies.
A new study finds that mastectomies do not completely eliminate the need for postoperative imaging and biopsy. For 10% to 15.5% of patients, subsequent imaging is required, and 6-8% undergo biopsy, with low malignancy rates.
A recent study found that palbociclib, a breast cancer drug, can effectively treat acute myeloid leukaemia (AML) with reduced toxicity compared to current chemotherapy. This breakthrough could lead to improved survival rates for patients with the serious condition.
A new study suggests targeting collagen XIII could suppress breast cancer metastasis by enhancing anoikis resistance in cancer cells. Researchers found that collagen XIII expression is significantly higher in cancerous human breast tissue and necessary for metastasis in mouse models.
A study published in CANCER found that weight loss in postmenopausal women is associated with a 12% lower risk of invasive breast cancer. Women who lost 5% of their body weight had a lower risk, while those who gained weight had an increased incidence of triple negative breast cancer.
Scientists have found that low TIP60 expression leads to uncontrolled jumping gene expression, triggering tissue inflammation that supports tumor growth. The discovery opens new avenues for cancer treatment using anti-HIV drugs.
Researchers at MUSC Hollings Cancer Center aim to find a less toxic, more effective treatment for metastatic breast cancer using a novel therapeutic antibody and innovative molecular imaging tools. The study will investigate the calcineurin/NFAT pathway's role in tumor growth and its potential inhibition by the antibody.
Researchers have identified estradiol as a potential new treatment for triple-negative breast cancer with estrogen receptor beta expression, effectively inhibiting tumor growth in studies. Estradiol stimulates the expression of cystatins, which exhibit tumor-suppressing effects on neighboring and distant cancer cells.
The ESMO 2018 Congress will feature a wide range of topics including immunotherapy, biomarkers, and prevention. The event will also host the annual congress of the European Oncology Nursing Society and a patient advocacy track emphasizing the central role of patients in securing access to optimal cancer care.
According to Dr. Holly Pederson, genetic testing can help identify patients at risk of breast cancer and reduce their chances of survival. The presentation highlights the importance of early screening and advances in cancer genetics, making it possible to save lives through preventive medications and surgical procedures.
A new computational approach has been developed to analyze large databases of clinical and splicing information for thousands of tumors. The software detects patterns of similarities between cases and identifies molecular alterations associated with patient survival and resistance to therapy.